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Abstract  
 
Melanoma is considered the most dangerous form of skin cancer, and the number of cases of 
melanoma per year has doubled in 30 years. Mutations in the B-RAF gene account for 
approximately 50% of genetic driver mutations in skin melanoma. Patients with B-RAF mutant 
melanoma are typically treated with a chemotherapy drug called vemurafenib. However, patients 
can stop responding to this treatment in as little as six months.  The main purpose of this study 
was to determine if inhibiting PAK, a kinase-signaling molecule, in combination with 
vemurafenib could prevent the treatment-resistance in melanoma. PAK signaling plays an 
important role in the Hippo tumor suppressor pathway, which is important in cell proliferation 
and growth. In order to evaluate the effects of PAK kinase inhibition, we utilized a drug called 
FRAX-486, which is a type of PAK kinase inhibitor in combination with vemurafenib to treat 
melanoma cells in cell growth experiments. The main findings suggest that PAK inhibition with 
vemurafenib prevents cell proliferation in the cancer cells. Therefore, these results support the 
conclusion that PAK kinase inhibition in combination with vemurafenib can prevent emergence 
of treatment resistant melanoma. This new combination treatment could have the potential to 
prevent or delay the emergence of treatment-resistant melanoma and prolong the patient’s life.  
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Introduction 
Melanoma is a type of cancer arising from melanocytes, the cell type that produces the 
pigment in skin. Melanoma is considered the most dangerous form of skin cancer (MacGill, 
2018). The number of cases of melanoma per year has doubled from 1982 to 2011. In 2011, in 
the United States alone, there were over 65,000 cases of melanoma, and over 9,000 deaths 
caused by melanoma (Guy et al., 2015). Mutations in the B-RAF gene account for approximately 
50% of genetic mutations in melanoma, and have been found in about 7-15% of cancers 
(Dhomen & Marais, 2007) (Curtin et al., 2005). Inhibition of the B-RAF kinase is a common 
target for treatment of melanoma because it is a commonly seen mutation found in the oncogenic 
cells. Vemurafenib is used to treat metastatic melanoma containing the B-RAFV600 mutations. 
Vemurafenib is an orally administered drug that inhibits the oncogenic B-RAF kinase. 
There are 3 primary highly conserved RAF serine-threonine protein kinase genes (A-RAF, B-
RAF, C-RAF) that function in the RAS-RAF-MEK-ERK pathway. The RAS-RAF-MEK-ERK 
pathway is a kinase cascade that is responsible for transmitting signals from extracellular growth 
factors, which play a role in many processes such as cell cycle progression, differentiation, 
survival, and migration (Molina Jr., 2006).  
This treatment is effective, with a report of a response rate as high as 84% in B-RAFV600 
melanoma treated with the B-RAF-targeted therapy (Chapman, 2011).  However, the cancer cells 
can develop resistance to vemurafenib in as short as 6 months (Chapman, 2011). The resistant 
cells display an increase in actin stress fiber formation, indicating resistance involves actin 
cytoskeletal remodeling (Kim, et al., 2016). Monomeric GTPases regulate cystoskeletal 
rearrangements. PAK kinase signaling downstream of Rac1 (GTPase) results in increased actin 
polymerization. PAK kinase also has the potential to activate YAP and TAZ, proto-oncogenic 
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transcriptional co-activators. B-RAF inhibitor resistant cells are shown to have an increase in 
actin stress fiber formation, and increased accumulation of YAP and TAZ in the nucleus. 
Overexpression of constitutively active YAP has also shown to cause resistance (Kim, et al., 
2016). It has been concluded that YAP/TAZ activation in cancer cells is oncogenic and 
stimulates resistance to anti-cancer drug therapies (Kim et al., 2016). PAK is a possible 
contributor to the emergence of vemurafenib resistance because of its potential to activate YAP 
and TAZ. 
PAK, also known as p21-activated kinase, is a member of a family of enzymes that serve 
as targets for small GTP binding proteins. PAK is a possible contributor to vemurafenib 
resistance because of its potential to activate YAP and TAZ, the proto-oncogenic transcriptional 
co-activators that are the targets of the Hippo tumor suppressor pathway. Typically, this 
signaling pathway plays key roles in the biological processes of organ size control, cell 
proliferation and apoptosis, stem cell homeostasis, and cellular differentiation (Kim et al., 2016). 
PAK signaling downstream of Rac1 is a possible activator of YAP and TAZ (Fig 1). 
Rac1 stimulates the PAK kinase proteins, which in turn activates LIMK. LIMK is an actin-
binding kinase that subsequently phosphorylates and inactivates the actin-severing protein 
cofilin, which in turn favors actin polymerization and F-actin accumulation.  Subsequently, F-
actin is binding AMOT, dislodging YAP, which then goes to the nucleus to initiation gene 
expression leading to abnormal cell growth (Feng, 2014). This potential pathway could explain 
the upregulation of YAP and TAZ as well as actin remodeling seen in resistant cells (Fig 1).  
It is known that YAP/TAZ activation of the Hippo pathway and actin remodeling result 
in emergence of treatment-resistant melanoma, however the role of upstream signaling by PAK 
kinases in resistance remains largely unexplored (Kim et al., 2016). Successful long term 
 3 
outcomes of the research presented here may include the ability to shut down this pathway 
through a PAK kinase inhibitor to prevent the development of vemurafenib-resistant cells. Here 
we report the effects of PAK kinase inhibition on emergence of vemurafenib resistance and on 
some of the signaling proteins that lie downstream of PAK that might contribute to drug 
resistance. 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: Schematic representation of Hippo-dependent and Hippo-independent pathways 
resulting in YAP activation (Feng, 2014). 
PAK 
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In order to evaluate the effects of PAK kinase inhibition, we utilized a drug called 
FRAX-486, which is a type of PAK (p21-activated kinase 1) kinase inhibitor (Chow et al., 
2012). To test the effects of PAK kinase inhibition on vemurafenib resistance, we completed a 
population doubling versus time experiment. Cells were treated with four different conditions: a 
negative control, vemurafenib alone, FRAX-486 alone, and a combination of FRAX-486 and 
vemurafenib. The cell populations’ doubling over time were examined to determine how the 
conditions affected cell growth and proliferation. Western blots were completed with to examine 
the effect of FRAX-486 treatment on signaling proteins in the treated cells. Proteins associated 
with the predicted path of resistance, as well as up and downstream components of PAK kinase 
signaling were examined. Overall based on the in vitro studies, PAK inhibition seems to be an 
ideal potential target for preventing treatment-resistance in patients. In future research, the PAK 
inhibition coupled with vemurafenib should be tested with small animal trials to evaluate results 
and possible side effects in an in vivo model.   
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Materials and Methods 
Reagents  
Vemurafenib was purchased from LC Laboratories, and FRAX-486 was purchased from 
Selleckchem. Vemurafenib was used at 3 μM and FRAX-486 was used at 50 nM. These were 
each dissolved in dimethyl sulfoxide.  
 
Cell Culture 
A375 cells were purchased from ATCC.  Prior to this study, the cells had been transduced with 
firefly luciferase to enable bioluminescence imaging of viable cells. Growth media was prepared 
with DMEM 1X media, 50 mL 10% Fetal Bovine Serum, 5 mL Penicillin (100 U/mL) 
/Streptomycin (100 μg/mL) solution, 5 mL MEM Non-Essential Amino Acids, and 2 mL L-
glutamine.  Cells were plated at 300,000 cells in a six well plate to begin the experiment. The 
cells were grown under four primary conditions: a negative control (no drug treatment), 
vemurafenib alone, FRAX-486 alone, and vemurafenib and FRAX-486 in combination. 
 
Drug Resistance Assay 
Growth media was replaced every 4 days. Cells were harvested, counted, and replated as 
tolerated during the growth experiment. Cell culture was terminated when treated cells either 
died out or developed resistance to the drug treatment. Cell populations were deemed resistant 
once they had achieved 10 population doublings under continuous drug treatment. The data was 
subsequently graphed and analyzed by GraphPad Prism software.  
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Cell viability assay  
For FRAX-486 dose–response analysis, luciferase-expressing cells were treated with variable 
doses of FRAX-486 in a 96-well plate and incubated for 24 h after plating. For each condition (0 
nM, 50 nM, 100 nM, 200 nM, 500 nM, 1000 nM, 5000 nM, 10,000 nM) six wells were plated 
with 5,0000 cells each. A bioluminescence imager quantified viable cells. Data was analyzed by 
using GraphPad Prism software.   
 
Antibodies  
Primary antibodies used for western blot experiments are shown in Table 1 below. 
Table 1: Antibodies utilized in Western Blot Experiments 
Name Dilution Isotype Purchasing Company Catalog number 
AKT 1000X Mouse BD Transduction 610860 
Phospho-AKT 2000X Rabbit Cell Signaling Technology 4060S 
Phospho-ERK 1000X Rabbit Cell Signaling Technology 9101S 
MEK 1000X Mouse Cell Signaling Technology 2352S 
Phospho-MEK 1000X Rabbit Cell Signaling Technology 98105S 
PAK 1/2/3 1000X Rabbit Cell Signaling Technology 2604 
Tubulin 1000X Rabbit DSHB 12G10 
 
Secondary antibodies were goat HRP-conjugated anti-mouse IgG and anti-rabbit igG purchased 
from Jackson ImmunoResearch.  
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Western Blot 
To prepare protein lysates, cells were seeded in 60 mm dishes and treated and grown for the 
indicated time points at 37°C in full growth media. Cells were transferred to ice, washed with 
ice-cold HBSM buffer (20 mM Hepes, pH 7, 150 mM NaCl, 2 mM CaCl2, 5 mM MgCl2 
dissolved in H2O), and lysed by Triton X-100 lysis buffer with 2 mM phenylmethylsulfonyl 
fluoride (PMSF).  Protein concentration of each lysate was measured using a Red 660 assay kit 
(G-Biosciences). Lysates were loaded at equal protein amounts of 20 µg per lane into a 9% SDS 
page gel, and subsequently transferred to a nitrocellulose membrane. After blocking with 
Aquablock (EastCoast Bio), membranes were incubated with primary antibodies diluted 1:1,000 
in Aquablock with 0.1% Tween 20. The primary antibody was stained overnight in at 4oC. The 
secondary antibody was diluted 1:1,000 in Aquablock with 1% Tween 20, and stained at room 
temperature for 1 hour. Membranes were scanned on an Odyssey CLx scanner (Licor) with 700 
and 800 nm channels set to membrane and normal or low resolution. Protein levels were 
quantified with the Image Studio software, by utilizing the built-in quantification tool that 
corrects for background noise.  
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Results 
 
PAK Inhibition Prevents Resistance in Melanoma  
 
In order to examine the effects of the PAK kinase inhibitor FRAX-486 on cell viability 
we completed a dose response curve with the following concentrations (in nM): 0, 50, 100, 200, 
500, 1000, 5000, 10000 (Fig 2.A). This graph fits the expected logarithmic form. Concentrations 
towards the right end of the graph indicate highly toxic amounts of the drug that result in cell 
death.  To limit cytotoxicity, 50 nM, a concentration similar to the IC20 as calculated from the 
dose-response curve, was chosen for subsequent assays. This concentration was chosen with the 
expectation that there would be little to no effect alone, but could be successful when used in 
combination with vemurafenib.  
Subsequent cell culture assays were completed in two independent experiments in order 
to examine the effects of vemurafenib and FRAX-486 in combination, in comparison to a DMSO 
vehicle control, FRAX-486 alone, and vemurafenib alone. The second experiment included 3 
biological replicates run in parallel. The cumulative population doubling is plotted on the y-axis, 
while time in days is plotted on the x-axis. In both experiments, cells under vemurafenib + 
FRAX treatment died out around days 55-60 (Fig 2.B & 2.C). The control treatment (DMSO) 
and FRAX alone reached 10 population doublings in as little as less than 15 days (Fig 2.B). The 
vemurafenib treated cells reached 10 population doublings at an average of 69 days, while 
increased growth can be noted on average around 35 days indicating vemurafenib treatment 
alone did not prevent development of drug-resistance in the cells. 
Short-Term Biochemical Assay Shows Inconclusive Results of VEM+FRAX Treatment 
In order to assess the potentially involved proteins and pathways for blockage of 
resistance by PAK kinase inhibition, lysates were generated and immunoblotted for various  
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Figure 2.   PAK Kinase Inhibition Prevents Resistance in Melanoma Cell Line 
A Dose response curve for PAK Kinase Inhibitor (FRAX-486). Bars indicate the standard 
error of the mean of the six wells per condition. The x-axis indicates the log 
concentration of FRAX-486, while the y-axis indicates the percentage of viable cells.  
B Population doublings vs. time graph evaluated the effects of treatment. This represents a 
single trial of a cell assay. Cells were re-fed with corresponding treatment every 4-5 days. 
DMSO and FRAX alone treatments reached 10 population doublings within 15 days. 
Vemurafenib treatment reached 10 population doublings around 81 days. The VEM-
FRAX combination treatment cells died off by day 60.  
C Population doublings vs. time graph evaluated the effects of treatment. This graph 
represents three trials run simultaneously. Cells were re-fed with corresponding treatment 
every 4-5 days. Vemurafenib treatment reached 10 population doublings on average by 
65 days. The VEM-FRAX combination treatment cells died off by around day 55.  
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potential proteins (see Figure 1) involved in vemurafenib resistance. Proteins involved in the 
MAP-kinase pathway targeted for treatment with vemurafenib were also tested. Tubulin served 
as the loading control for equal amounts of protein sample loading.  
When comparing the cells under vemurafenib (VEM) treatment and the vemurafenib and 
FRAX-486 combination (VEM+FRAX) treatment we expected to see a down-regulation of TAZ, 
pERK, and pAKT and/or AKT in the VEM+FRAX cells because these proteins are associated 
with resistance in melanoma. We also expected to see a down-regulation of phosphorylation of 
MEK at position 298 in the VEM+FRAX cells because this position on MEK is phosphorylated 
by activated PAK.  
Overall, there were no dramatic changes in any of the signaling protein levels when 
comparing the vemurafenib treated cells with the VEM+FRAX combination (Fig 3). The protein 
levels of TAZ, pMEK, pAKT, and pERK are all highest in the DMSO and FRAX treated cells, 
while they are significantly lower in both the VEM treated and VEM+FRAX treated cells. The 
protein levels of TAZ and pMEK moderately decrease with time in both the VEM treated and 
VEM+FRAX treated cells. Interestingly, the protein levels of pERK was significantly 
diminished by day 2 of treatment and then moderately increased by day 7 in both the VEM 
treated and VEM+FRAX treated cells. These results indicated either the mechanism by which 
PAK inhibition blocks drug resistance has not been identified, or that the PAK inhibition 
mechanism is functioning at sub-detectible levels during the beginning of treatment.  
 
PAK Inhibitor Concentration Levels in Relation to pMEK S298 Signal Inhibition 
In order to assess the relationship of FRAX 486 concentration and the inhibition of the 
downstream target of PAK, lysates were generated from cells treated with the following  
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Figure 3.   Protein involvement in resistance prevention via VEM+FRAX is inconclusive 
Immunoblotting for the indicated proteins, quantification for relative intensity of the band can be 
seen underneath each lane. The protein levels of TAZ, pMEK, pAKT, and pERK are all highest 
in the DMSO and FRAX treated cells, while they are significantly lower in both the VEM treated 
and VEM+FRAX treated cells. The protein levels of TAZ and pMEK moderately decrease with 
time in both the VEM treated and VEM+FRAX treated cells. The protein levels of pERK was 
significantly diminished by day 2 of treatment and then moderately increased by day 7 in both 
the VEM treated and VEM+FRAX treated cells. Tubulin served as the positive loading control.  
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concentrations of FRAX 486 (in nM): 0, 50, 100, 200, 500, 1000. They were subsequently 
blotted for total MEK and pMEK S298, the target site for PAK signaling. Tubulin served as the 
loading control for equal amounts of protein sample loading. The relative amount of pMEK S298 
and total MEK decreased with increasing concentrations of FRAX 486 (Fig 4.A).  
A dose response curve was created to visualize the percentage of target inhibition. From 
this graph, the IC50 was calculated to be 540 nM (Fig 4.B). The IC50 for target inhibition 
corresponds to the concentration of FRAX 486 that inhibits 50% of the amount of pMEK S298 
in untreated cells.  
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Figure 4.  Dose Response Curve for FRAX 486 Target Inhibition.  
A Immunoblotting for the indicated proteins at varying levels of PAK inhibitor 
concentrations; quantification for relative intensity of the band can be seen underneath 
each lane. PAK inhibition results in a decreased level of phosphorylated MEK and total 
MEK. Tubulin served as the loading control.  
B Dose response curve for PAK Kinase Inhibitor (FRAX-486). The x-axis indicates the log 
concentration of FRAX-486, while the y-axis indicates the percentage of the pMEK 
signal inhibited by FRAX 486.  
A 
B 
- - - - IC50 = 540 nM 
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Discussion 
This study aimed to evaluate the effects of PAK kinase inhibition on emergence of 
vemurafenib resistance and potentially related biochemical signaling pathways. Our results 
strongly indicate that combining PAK kinase inhibition via FRAX-486 with vemurafenib 
treatment can prevent development of resistance in melanoma cells. In the cell culture assays, 
cells under vemurafenib treatment alone began to show signs of resistance by day 35 on average. 
However, cells under VEM-FRAX combination treatment eventually died out between days 55-
60, and resistance was never developed. Treatment with FRAX alone showed no effect on cell 
growth in comparison to the DMSO control. This provides evidence that the FRAX treatment at 
the 50 nM dose we chose may not result in cytotoxicity in normal cells; there may be minimal to 
no effects. Furthermore, these results indicate that PAK kinases are playing an important role in 
the development of resistance in melanoma cells.  
According to the short-term biochemical assay, there were no significant differences in 
the levels of selected signaling proteins within the first seven days of treatment. However, there 
are several possible explanations for this observation. Phosphorylation of MEK at the 298 
position is associated with activation by PAK. One possible way the treatment of PAK kinase 
inhibition is effective is through deactivation of PAK and subsequent effects on cell proliferation 
occurring at sub-detectible levels at the beginning of treatment. The protein levels of pERK are 
highest in the DMSO and FRAX treated cells.  The protein levels of pERK are extremely 
diminished in the VEM and VEM+FRAX treated cells. There was a two fold increase from day 2 
to day 7 in pERK in the VEM and VEM+FRAX treated cells. It is possible the cells begin to 
combat the vemurafenib treatment by attempting to reactivate the ERK protein by 
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phosphorylation. Although not tested in this study, PAK kinase inhibition may work to prevent 
resistance by having a slow build up over time of cumulative inhibition of ERK phosphorylation.  
The inconclusive results of the short-term biochemical assay are further rationalized by 
the results of the FRAX 486 concentration vs. pMEK S298. These concentration lysates were 
used to determine the signaling IC50 of 540 nM for the FRAX 486 drug. For the drug resistance 
experiments we chose a FRAX 486 concentration close to the IC20, 50 nM. This value is 
significantly lower, which leads us to believe that the blockage of resistance is taking place at a 
sub-detectible level in the short term.  
This study faced constraints mostly due to time. The results from the short-term 
biochemical assays were difficult to draw conclusions from. Moving forward, biochemical 
assays on long-term lysates need to be assessed. In the drug-resistance assays differences 
between cell treatment growths weren’t seen until around days 20-30. Ideally, when making the 
new lysates, they should be from cells grown under the treatment conditions until at least day 30.  
Previous studies have shown increased PAK-1 expression in cancers of the bladder, 
breast, lung, and T cell lymphomas (Ong et al., 2011)(Field and Ye, 2015)(Pandolfi et al., 
2015)(Gan et al., 2016). However, the role of PAK in metastasis with relation to the Hippo 
pathway was not explored. As discussed in previous literature, PAK seems to play an essential 
role cancer metastasis. Developing a potential treatment to target PAK would be beneficial in a 
large number of cancers.   
Previous research has also linked PAK signaling directly to resistance in B-RAF mutant 
melanomas like studied here (Lu et al., 2017). However, the major focus in Lu et al. was on the 
MAP Kinase pathway. The potential role of the Hippo pathway was not explored despite the 
evidence of cytoskeletal rearrangement in drug-resistant melanoma. Furthermore, the effects of 
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PAK inhibition with the common B-RAF inhibitor was only studied after the cells developed 
resistance to the B-RAF inhibitor treatment. The avenue of potential preventative treatment was 
not investigated (Lu et al., 2017).  
Another future avenue for this project involves evaluating the role of Src/PAK signaling 
in vemurafenib resistant melanoma. It has been shown that oncogenic Src results in cancerous 
cellular transformation through activation of Rac1 (Servitja, et al., 2003). It is possible that 
vemurafenib resistance is developed through a pathway involving Src signaling through Rac1, 
and subsequent downstream signaling through PAK. 
In conclusion, PAK appears to play an important role of development of resistance in 
vemurafenib treated B-RAF melanoma. This means PAK kinase inhibition could be an 
extremely important therapeutic target moving forward. Further investigation into the 
mechanism will provide insight to the cancer community, as it is possible PAK kinase is an 
important factor in a variety of cancers. Subsequent animal trials will allow evaluation of the 
potential treatment in an in vivo setting.  
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